Experiences of serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT)

Experiences of serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT)

Background: This study aims to provide evidence of factors that impact participant reported serious depression and serious anxiety among individuals receiving injectable opioid agonist treatment (iOAT). Methods: Data from an 18-month longitudinal retrospective cohort of individuals receiving iOAT wa...

Full description

Bibliographic Details
Main Authors:	Tianna Magel, Ying C MacNab, Scott MacDonald, Eugenia Oviedo-Joekes
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	Journal of Affective Disorders Reports
Subjects:	Depression Anxiety Injectable opioid agonist treatment Opioid use disorder Person-centered care
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666915323002329

Similar Items

Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT)
by: Scott Beaumont, et al.
Published: (2024-01-01)

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study
by: Dobischok S, et al.
Published: (2022-12-01)

Changes in daily dose in open-label compared to double-blind: The role of clients’ expectations in injectable opioid agonist treatment
by: Sarin Blawatt, et al.
Published: (2023-06-01)

Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study
by: Eugenia Oviedo-Joekes, et al.
Published: (2023-05-01)

Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment
by: Kirsten Marchand, et al.
Published: (2020-01-01)

The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review
by: Alison Adams, et al.
Published: (2023-09-01)

Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study
by: Eugenia Oviedo-Joekes, et al.
Published: (2021-03-01)

Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment
by: Heather Palis, et al.
Published: (2021-09-01)

“As long as that place stays open, I’ll stay alive”: Accessing injectable opioid agonist treatment during dual public health crises
by: Kaitlyn Jaffe, et al.
Published: (2023-04-01)

First-line opioid agonist treatment as prevention against assisting others in initiating injection drug use: A longitudinal cohort study of people who inject drugs in Vancouver, Canada
by: Zachary Bouck, et al.
Published: (2023-06-01)

Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder
by: Ashish P. Thakrar, et al.
Published: (2023-02-01)

Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study
by: Cayley Russell, et al.
Published: (2022-03-01)

Applying the socio-ecological model to understand community reintegration experiences among individuals on opioid agonist treatment (OAT) released from federal incarceration in Ontario, Canada
by: Cayley Russell, et al.
Published: (2022-12-01)

Biphalin—A Potent Opioid Agonist—As a Panacea for Opioid System-Dependent Pathophysiological Diseases?
by: Patrycja Redkiewicz, et al.
Published: (2021-10-01)

Prevalence of alcohol consumption among clients of opioid agonist treatment (OAT) centers in Golestan province, Iran
by: Alireza Noroozi, et al.
Published: (2023-05-01)

A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data
by: Kristen A. Morin, et al.
Published: (2020-07-01)

Is use of opioid agonist treatment associated with broader primary healthcare use among men with recent injecting drug use histories following release from prison? A prospective cohort study
by: Michael Curtis, et al.
Published: (2023-03-01)

Psychiatrist-led treatment of hepatitis C (HCV) at an opioid agonist treatment (OAT) clinic in Stockholm - enhancing the HCV treatment care cascade
by: M. Kåberg, et al.
Published: (2022-06-01)

<it>In vivo </it>antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera
by: Guillemyn Karel, et al.
Published: (2012-01-01)

The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: findings from the OATS retrospective linkage study.
by: Nicola Jones, et al.
Published: (2022-08-01)

Prevalence of COVID-19 outcomes in patients referred to opioid agonist treatment centers
by: Samira Khani, et al.
Published: (2023-03-01)

Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy
by: Soroush Moallef, et al.
Published: (2022-12-01)

Interim opioid agonist treatment for opioid addiction: a systematic review
by: Laura Samsó Jofra, et al.
Published: (2022-01-01)

Care cascade for patients with opioid use disorder and serious injection related infections
by: Anand Upadhyaya, et al.
Published: (2021-11-01)

Agonists Specific for κ-Opioid Receptor Induces Apoptosis of HCC Cells Through Enhanced Endoplasmic Reticulum Stress
by: Mengyuan Tan, et al.
Published: (2022-03-01)

In vitro and in vivo Pharmacological Activities of 14-O-Phenylpropyloxymorphone, a Potent Mixed Mu/Delta/Kappa-Opioid Receptor Agonist With Reduced Constipation in Mice
by: Roberta Lattanzi, et al.
Published: (2018-08-01)

Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review
by: Em M. Pijl, et al.
Published: (2022-08-01)

Erratum: Agonists Specific for κ-Opioid Receptor Induces Apoptosis of HCC Cells Through Enhanced Endoplasmic Reticulum Stress
by: Frontiers Production Office
Published: (2022-05-01)

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report
by: Heather Palis, et al.
Published: (2021-05-01)

Role for μ-opioid receptor in antidepressant effects of δ-opioid receptor agonist KNT-127
by: Yuki Moriya, et al.
Published: (2023-03-01)

Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment
by: Marchand Kirsten, et al.
Published: (2012-01-01)

Opioid agonist treatment take-home doses (‘carries’): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA?
by: Cayley Russell, et al.
Published: (2022-08-01)

Recent Molecular Insights into Agonist-specific Binding to the Mu-Opioid Receptor
by: Ferenc Zádor, et al.
Published: (2022-06-01)

Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada
by: Cayley Russell, et al.
Published: (2022-12-01)

Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study
by: Anne Berit Bech, et al.
Published: (2019-07-01)

A Facile Synthesis for Novel Loperamide Analogs as Potential &#956; Opioid Receptor Agonists
by: Xiaofeng Bao, et al.
Published: (2012-12-01)

Precautions in the management of opioid agonist therapy: from target population characteristics to new formulations and post-marketing monitoring – a focus on the Italian system
by: Guido Mannaioni, et al.
Published: (2023-01-01)

Measuring sustainability of opioid agonist therapy programs in the context of transition from Global Fund support
by: Raminta Stuikyte, et al.
Published: (2024-01-01)

Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities
by: Zoe Friedmann, et al.
Published: (2023-11-01)

Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework
by: Farah Tahsin, et al.
Published: (2022-04-01)